Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Hematology (blood)

  • Article

    Consider Platelet Transfusion Prior to CVC Placement for Patients with High-risk Thrombocytopenia

    September 1, 2023

    Dr. Meyer Clinical question: Can central venous catheters (CVC) be safely placed in patients with platelet counts less than 50,000 without administration of platelets prior to the...

  • 1
    News

    Anticoagulant choice in antiphospholipid syndrome–associated thrombosis

    December 10, 2021

    Are direct oral anticoagulants (DOACs) as efficacious and safe as vitamin K antagonists (VKAs) in treating thrombosis secondary to antiphospholipid syndrome (APS)?

  • 1
    News

    Apixaban a reasonable alternative to warfarin in patients with severe renal impairment

    December 9, 2021

    Is apixaban a safe alternative to warfarin in patients with severe renal impairment?

  • 1
    News

    Apixaban outmatches rivaroxaban for VTE in study

    December 6, 2021

    These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.

  • 1
    News

    Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE

    December 6, 2021

    Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?

  • News

    Rituximab likely raises risk of hospital death in COVID-19 patients

    December 2, 2021

    In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”

  • 1
    News

    Tranexamic acid does not reduce risk of death in GI bleed

    December 2, 2021

    In patients with GI bleeding, does high-dose tranexamic acid (TXA) reduce the risk of death?

  • 1
    News

    Oakland score identifies patients with lower GI bleed at low risk for adverse events

    November 23, 2021

    Is the Oakland score a valid tool to assess the risk of adverse outcomes in adult patients with acute lower GI bleed (LGIB)?

  • 1
    News

    Timing of endoscopy for acute upper GI bleeding

    November 18, 2021

    In high-risk patients hospitalized with upper GI bleeding, is earlier endoscopy beneficial?

  • 1
    News

    Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT

    November 17, 2021

    The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.

Previous1 2 3 4 … 13Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences